1. Scrip
  2. >>Business
  3. >>Earnings

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Like a number of big pharma players, Sanofi is investing heavily in expanding its production footprint in the US but chief financial officer François Roger has talked up the importance of Europe to the French firm’s future a day after CEO Paul Hudson questioned the attraction of investing at home.

Key Takeaways
  • Sanofi had already been upping its investment in the US before the uncertainty that potential tariffs has brought to the sector
  • It has also been investing in the EU but is concerned about Europe's capacity to properly value innovation

Hudson and Novartis CEO Vas Narasimhan’s letter in the Financial Times on 23 April called on the EU to strengthen its domestic market and incentivize rather than penalize innovation in the sector, saying that “waning European biopharma competitiveness [and] the uncertainty of tariffs is further reducing incentives to invest” in the continent. The letter came at a time when the likes of Roche and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Blood and Clotting

Regeneron Will Move Two Factor XI Agents Into Phase III

 
• By Joseph Haas

With successful Phase II data versus active comparators for both REGN7508 and REGN9933, Regeneron hopes to position the candidates to compete against existing factor X products.

ASH: Pfizer’s Hemophilia A Gene Therapy May Have Slight Liver Safety Advantage

 
• By Mandy Jackson

Hematologists’ concerns about hepatoxicity with hemophilia A gene therapies may limit use, but Phase III data for Pfizer’s candidate at ASH show a lower rate of ALT increases than seen with BioMarin’s Roctavian.

Keros Monetizes Hematology Asset In Deal With Takeda

 
• By Jessica Merrill

Takeda will pay $200m up front for rights to Phase II elritercept for anemia in patients with MDS and myelofibrosis, allowing Keros to extend its cash runway to 2028.